CHC

:   chronic hepatitis C

HCV

:   Hepatitis C virus

HIV

:   human immunodeficiency virus

SVR

:   sustained virologic response

Introduction {#ss1}
============

Hepatitis C virus (HCV) is a major cause of chronic liver disease and hepatocellular carcinoma, and is the leading indication for liver transplantation. In the US alone, approximately 4 million people are infected, of whom 10 000 die each year as a consequence of HCV‐related liver disease \[[1](#b1){ref-type="ref"}\]. The standard of care for treatment of chronic hepatitis C (CHC) infection has evolved in a stepwise progression over the past 10 years. Interferon‐alpha 3 million units (MU), given through subcutaneous injection three times weekly, resulted in sustained virologic response (SVR) in 10--20% of patients, whereas combination interferon‐alpha/ribavirin achieved overall response rates approaching 30--40% \[[2](#b2){ref-type="ref"}, [3](#b3){ref-type="ref"}, [4](#b4){ref-type="ref"}\]. Two forms of a newer, longer‐acting pegylated interferon‐alpha have provided an incremental advantage over standard interferon, and in combination with ribavirin can achieve SVRs between 40 and 80% depending on the HCV genotype \[[5](#b5){ref-type="ref"}, [6](#b6){ref-type="ref"}\]. Despite these advances, a significant number of patients fail to respond to the current standard antiviral regimen, especially in patients with unfavourable features such as genotype 1 infection and high viral load, which were the majority of patients in the US with CHC. In the coming years, we will be facing an increasing proportion of such patients and/or treatment failures. While antiviral agents specifically targeting key enzymes of the HCV viral cycle remain under investigation, alternative agents such amantadine may represent important adjunctive treatment options, especially for the growing patient population that have failed prior anti‐viral therapy.

The first report demonstrating the efficacy of amantadine in treatment of CHC was published in 1997, when Smith and colleagues described a group of 22 patients who failed interferon‐alpha monotherapy and 18% subsequently cleared virus when re‐treated with amantadine 100 mg twice daily for 6 months \[[7](#b7){ref-type="ref"}\]. Since this initial report, clinical studies have provided conflicting results on amantadine when used alone, in combination with interferon‐alpha, or with interferon‐alpha and ribavirin. Most studies suggest that amantadine has little impact on SVR when used alone, and produces at best a modest improvement in SVR when combined with interferon‐alpha or interferon‐alpha plus ribavirin. In this review we investigate the potential role of amanatidine, in the treatment of CHC based on results published up to end of 2003.

Mechanism of action {#ss2}
===================

Amantadine (1‐aminoadamantanamine) is a water soluble tricyclic amine that has been used clinically to prevent influenza A viral infection, and has known antiviral effects against other families of RNA viruses such as togavirus, myxovirus, coronavirus and flavivirus, of which hepatitis C is a member \[[8](#b8){ref-type="ref"}\]. This effect is mediated by inhibition of an early step in influenza A viral replication through interaction with the M2 viral membrane matrix protein, which functions as an ion channel, and is required for internalization of the virus by endocytosis \[[9](#b9){ref-type="ref"}\].

The mechanism of amantadine as an antiviral agent for hepatitis C remains uncertain. Early studies showed that amantadine reduced HCV RNA content in cultured peripheral blood mononuclear cells from infected patients \[[10](#b10){ref-type="ref"}\], and inhibit the HCV p7 protein, a key component of ion channel formation \[[11](#b11){ref-type="ref"}\]. Despite this observation, *in vitro* biochemical assays demonstrated that amantadine failed to inhibit key regulatory enzymes and steps of viral replication, including HCV protease, helicase, ATPase, RNA‐dependent RNA polymerase, and HCV internal ribosomal entry site translation \[[12](#b12){ref-type="ref"}\]. Any effect of amantadine on HCV likely involves an immune‐mediated process as amantadine may induce the production of interleukins \[[13](#b13){ref-type="ref"}\]. Therefore, amantadine may be best used as an adjunct to interferon and ribavirin to produce an additive or synergistic effect \[[14](#b14){ref-type="ref"}, [15](#b15){ref-type="ref"}\]. Additional research is needed to determine if amantadine interacts with other host or viral factors, or modulates the host immune system as a basis for its antiviral effects.

Methods {#ss3}
=======

A literature search was performed by using the MEDLINE database to identify publications between 1966 and December 2003. A MEDLINE keyword search was conducted using the MeSH terms: hepatitis C virus, chronic viral hepatitis and amantadine. The search was then limited to English‐language studies in adult humans. The reference lists of retrieved publications were then examined to identify additional citations. All article abstracts were reviewed to determine relevance to management of CHC infection, after which full text articles were obtained for further analysis. All clinical studies using amantadine for treatment of CHC were published since 1997. Clinical trials published between 1997 and 2003 with the use of amantadine for CHC formed the basis of this review.

Results {#ss4}
=======

Use of amantadine in treatment‐naïve patients with chronic hepatitis C infection {#ss5}
--------------------------------------------------------------------------------

### Amantadine as monotherapy or in combination with interferon {#ss6}

Thirteen clinical trials have studied the use of amantadine as first‐line treatment for CHC infection. Eighty‐nine patients in five observational trials were treated with amantadine 200 mg daily alone for 3--12 months; although a biochemical response was seen in some patients, none achieved a SVR \[[16](#b16){ref-type="ref"}, [17](#b17){ref-type="ref"}, [18](#b18){ref-type="ref"}, [19](#b19){ref-type="ref"}, [20](#b20){ref-type="ref"}\]. Six randomized trials were performed to evaluate interferon‐alpha and amantadine combination therapy as first‐line therapy. Caronia *et al*. \[[21](#b21){ref-type="ref"}\] demonstrated in their study of 143 patients that the addition of amantadine to fixed‐dose IFN‐alpha 4.5 MU three times weekly for 12 months had no additional improvement in SVR (18% without amantadine *vs* 15% with amantadine). In contrast, Mangia *et al*. \[[22](#b22){ref-type="ref"}\] found in their open‐label, prospective study of 200 patients that the addition of amantadine to fixed‐dose IFN‐alpha 6 MU three times weekly for 12 months resulted in a statistically significant increase of SVR from 16.8 to 29.3% (*P* = 0.036). A recent meta‐analysis of individual patient data for these six trials showed that combination interferon‐alpha and amantadine appears to be effective, resulting in a pooled SVR of 23.1% (*P* = 0.03) \[[23](#b23){ref-type="ref"}\]. In this meta‐analysis, 481 treatment naïve patients were treated with interferon and amantadine and 491 received interferon monotherapy. Baseline characteristics in favour of the interferon‐amantadine combination therapy over monotherapy included genotype 1 or 4 (*P* = 0.025), high viral load (*P* = 0.035), age \<40 (*P* = 0.023), low ALT level (*P* = 0.007) and absent to moderate fibrosis (*P* = 0.007). Logistic regression analysis showed interferon‐amantadine combination therapy (*P* = 0.04) in addition to age, genotype and baseline viraemia were independent predictors of response. In the most difficult to treat group (genotype 1 or 4, high viral load), the response rate using combination therapy was 10.5%*vs* 4.9% in the monotherapy group (*P* = 0.08), but response was similar among those with favourable genotype (2 or 3) and low viral load. The most important conclusion, perhaps, was the fact that amantadine did improve the response rate of interferon in treatment naïve CHC patients in this meta‐analysis. However, this was still below the SVR with current interferon and ribavirin combination therapy.

### Amantadine as induction therapy {#ss7}

Four randomized controlled trials evaluated the role of interferon in combination with amantadine induction therapy. Only one of the four trials showed the addition of amantadine to interferon during induction improved the SVR. Nakamura *et al*. \[[24](#b24){ref-type="ref"}\] studied 31 patients in whom the addition of amantadine 100 mg daily did not increase the SVR in patients receiving interferon‐beta 6 MU daily for 6 weeks, followed by 6 MU three times weekly for 26 weeks (0%*vs* 9%) (*P* = ns). Zeuzem *et al*. \[[25](#b25){ref-type="ref"}\] studied 119 patients in whom the addition of amantadine 200 mg daily did not increase SVR in patients receiving interferon‐alpha 6 MU three times weekly for 24 weeks, followed by 3 MU three times weekly for 24 weeks (10%*vs* 22%) (*P* = ns). Tabone *et al*. \[[26](#b26){ref-type="ref"}\] studied 180 patients in whom the addition of amantadine 200 mg daily did not demonstrate a statistically significant increase in SVR in patients receiving interferon‐alpha 6 MU on alternate days for 6 months, followed by 3 MU on alternate days for 6 months (24%*vs* 17%) (*P* = ns). Helbing *et al*. performed a double‐blind study of 246 patients who received interferon‐alpha 6 MU three times weekly for 20 weeks then 3 MU three times weekly for the remainder of a 12 month course, with or without amantadine 200 mg daily. The addition of amantadine resulted in a statistically insignificant increase in SVR from 17% to 24% (*P* = 0.175) \[[27](#b27){ref-type="ref"}\]. These trials suggest that amantadine induction therapy is ineffective.

### Amantadine in combination with interferon and ribavirin {#ss8}

Two randomized trials evaluated the role of triple therapy with interferon‐alpha, ribavirin, and amantadine in management of treatment‐naïve patients. Ullerich *et al*. studied 30 patients in an open‐label, prospective study in which amantadine 200 mg daily and ribavirin 1000--1200 mg daily was given to all patients. Patients were then randomized to receive either low induction interferon‐alpha 6 MU three times weekly for 12 weeks then 3 MU three times weekly for 36 weeks, or high induction interferon‐alpha 9 MU three times weekly for 4 weeks, followed by 6 MU three times weekly for 4 weeks, 3 MU three times weekly for 4 weeks and 1.5 MU three times weekly for the final 36 weeks. The high induction interferon regimen resulted in a large but statistically not significant increase in SVR (67%*vs* 40%) (*P* = ns) \[[28](#b28){ref-type="ref"}\]. Berg *et al*. performed a large randomized, double‐blind trial of 400 patients, all of whom were given induction interferon‐alpha 9 MU daily for 2 weeks, followed by 6 MU daily for 6 weeks and 6 MU three times weekly for 40 weeks, in addition to weight‐based ribavirin 1000--1200 mg daily. Patients were then randomized to receive placebo or amantadine 100 mg twice daily. Patients receiving amantadine did not have a statistically significant increase in SVR (52%*vs* 43.5%, *P* = ns) \[[29](#b29){ref-type="ref"}\]. The SVR was higher in the amantadine group (39%*vs* 31%) in patients with genotype 1. In addition, multiple logistic regression analysis showed amantadine treatment was an independent factor associated with SVR. The finding of this study and the meta‐analysis of the amantadine--interferon combination therapy \[[23](#b23){ref-type="ref"}\] suggested there might be a beneficial effect of amantadine in genotype 1 patients.

### Summary {#ss9}

Current literature does not support the use of amantadine monotherapy as a first line treatment for CHC. Amantadine may have a limited role in combination with interferon‐alpha or interferon‐alpha plus ribavirin for management of treatment‐naïve patients, particularly in patients with genotype 1 and high viral load.

Use of amantadine for interferon nonresponders in hepatitis C infection {#ss10}
-----------------------------------------------------------------------

Eleven trials have evaluated the use of amantadine in treating patients with CHC infection who have previously failed interferon monotherapy. Three small observational studies involving a total of 44 patients demonstrated that monotherapy with amantadine 200 mg daily failed to result in SVR in any patient (0%) \[[30](#b30){ref-type="ref"}, [31](#b31){ref-type="ref"}, [32](#b32){ref-type="ref"}\]. Two small prospective studies evaluated the role of amantadine in combination with interferon‐alpha in re‐treatment of interferon nonresponders.

### Interferon and amantadine {#ss11}

Teuber *et al*. performed a randomized, double‐blind trial of 55 patients in whom the addition of amantadine 200 mg to interferon‐alpha 6 MU three times weekly for 24 weeks then 3 MU three times weekly for 24 weeks did not result in SVR (0%) (*P* = ns) \[[33](#b33){ref-type="ref"}\]. In a nonrandomized, prospective, open‐label trial in which patients were given interferon‐alpha 4.5 MU daily for 1 month then 6 MU three times weekly for 5 months, with or without amantadine 200 mg daily, the addition of amantadine did not result in a single case of SVR (0%) (*P* = ns) \[[34](#b34){ref-type="ref"}\]. The first randomized, prospective, open‐label trial by Khalili *et al*. \[[35](#b35){ref-type="ref"}\], who demonstrated in a cohort of 15 patients treated with amantadine 200 mg daily and 3 MU interferon‐alpha TIW was inferior to interferon and ribavirin 1000 mg daily (14 patients) for six months with SVR of 0%*vs* 15%, respectively (*P* = ns). In a randomized, double‐blind trial by Younossi and colleagues, 118 patients were re‐treated for 24 weeks with either of two regimens: (i) interferon‐alpha 3 MU three times weekly and ribavirin 800 mg daily, or (ii) interferon‐alpha 3 MU three times weekly and amantadine 200 mg daily. None of the patients receiving amantadine achieved a SVR; only 3.9% of patients receiving combination interferon‐ribavirin cleared the virus (*P* = 0.16) \[[36](#b36){ref-type="ref"}\]. These studies demonstrated that the combination of interferon and amantadine is ineffective.

### Amantadine in combination with interferon and ribavirin {#ss12}

The initial study by Berg *et al*. \[[32](#b32){ref-type="ref"}\] described 14 consecutive interferon nonresponders who were given induction therapy with interferon‐alpha 9 MU daily for 1 week, followed by 9 MU on alternate days for 5 weeks, 6 MU three times weekly for 6 weeks, and 3 MU three times weekly for 36 weeks, as well as ribavirin 1000--1200 mg daily and amantadine 200 mg daily. None of these patients achieved SVR. In contrast, three other studies suggested that amantadine triple therapy might be beneficial. In a pilot nonrandomized, prospective, open‐label trial of 20 patients, the addition of amantadine to interferon 5 MU on alternate days and ribavirin 800--100 mg daily resulted in a large, statistically significant increase in SVR (30%*vs* 0%) (*P* \< 0.0001) \[[37](#b37){ref-type="ref"}\]. A follow‐up randomized, open‐label trial of 60 patients by the same research group also demonstrated that the addition of amantadine resulted in a statistically significant increase in efficacy (48%*vs* 5%) (*P* \< 0.001) \[[38](#b38){ref-type="ref"}\]. Adinolfi *et al*. performed the largest randomized trial addressing this question, studying 114 patients who were randomized to three groups: (i) fixed dose interferon‐alpha 3 MU three times weekly and oral ribavirin 1000 mg daily, (ii) induction interferon‐alpha 3 MU daily (4 weeks) then 3 MU three times weekly plus oral ribavirin 1000 mg daily, or (iii) induction interferon‐alpha and ribavirin plus oral amantadine 200 mg daily, resulting in SVR of 2, 4 and 25% respectively (*P* = 0.002) \[[39](#b39){ref-type="ref"}\]. This study demonstrated that the combination of induction interferon‐alpha, ribavirin and amantadine resulted in statistically significant increases in SVR.

### Reasons for conflicting results {#ss13}

These conflicting findings are likely the result of uniformly small sample sizes and important differences in the treatment regimens. For example, in the meta‐analysis of treatment‐naïve patients, a sample size of 500 in each treatment arm was needed to detect the marginal increase in SVR with addition of amantadine \[[23](#b23){ref-type="ref"}\]. These studies were inadequately powered to detect a small benefit from amantadine. The study by Younossi *et al*. \[[36](#b36){ref-type="ref"}\] also has several shortcomings. Although the optimal duration of treatment with amantadine and interferon remains unknown, it is possible that the full antiviral effect of combination therapy was underestimated by the short‐course of treatment (24 weeks), as other studies have demonstrated that a minimum of 48 weeks of interferon is necessary to achieve sustained viral clearance in patients with genotype 1. Amantadine\'s antiviral effect may be mediated, in part, by unique synergistic interactions with interferon and ribavirin, and therefore may have been underestimated in trials not evaluating triple therapy. Additionally, its effect may have been underpowered by the low ribavirin dose used in this study (800 mg daily). Previous studies have clearly demonstrated that ribavirin exerts antiviral effects in a dose‐dependent manner, and therefore comparison with studies using higher doses cannot be made. In contrast, both the Brillanti \[[38](#b38){ref-type="ref"}\] and Adinolfi \[[39](#b39){ref-type="ref"}\] trials evaluated amantadine as a component of triple therapy for a full 48‐week course, and demonstrated impressive increases in SVR compared with the standard combination interferon--ribavirin regimen. The trial by Adinolfi \[[39](#b39){ref-type="ref"}\] was the best powered to address this question (114 patients), and additionally demonstrated that induction therapy with 4 weeks of daily interferon may have incremental benefit. Amantadine may have an important role as an adjunct to combination interferon--ribavirin therapy in interferon nonresponders, although further prospective, randomized trials are needed to further elucidate the optimal dosing and duration, and identify predictive factors for success.

### Summary {#ss14}

Current literature strongly suggests that amantadine is not effective as monotherapy or in combination with interferon for re‐treatment of interferon nonresponders. It may have a role as an adjunct to standard interferon‐alpha and ribavirin therapy in treatment of interferon‐nonresponders, although the current data is conflicting.

Use of amantadine in interferon/ribavirin nonresponders {#ss15}
-------------------------------------------------------

Three small observational studies have evaluated the efficacy of amantadine in treating patients who have failed to respond to combination interferon/ribavirin or both interferon monotherapy and interferon/ribavirin re‐treatment. DiMartino *et al*. treated 10 consecutive patients who failed either interferon or interferon/ribavirin with amantadine 100 mg daily for 12 months. Although this resulted in decreased ALT in all patients, none achieved SVR (*P* = ns) \[[40](#b40){ref-type="ref"}\]. Thuluvath *et al*. studied 23 consecutive interferon/ribavirin nonresponders by re‐treating all patients with triple combination therapy (interferon‐alpha 3 MU three times weekly, ribavirin 1000--1200 mg daily, and amantadine 200 mg daily) for 6--12 months. This resulted in a 13% SVR, suggesting that re‐treatment with combination therapy and amantadine may result in viral clearance in a small number of patients \[[41](#b41){ref-type="ref"}\]. Younossi *et al*. treated 20 consecutive interferon monotherapy and combination interferon/ribavirin nonresponders with triple combination therapy (interferon‐alpha 3 MU three times weekly, ribavirin 800 mg daily, and amantadine 200 mg daily) for 48 weeks, achieving SVR in two patients (10%) \[[42](#b42){ref-type="ref"}\].

### Summary {#ss16}

Amantadine may result in viral clearance in a small group of patients who have failed both interferon and combination interferon/ribavirin. The results of these trials are limited by small sample sizes, and therefore may be inadequate to support a definitive conclusion on the effects of amantadine in patients failing standard combination interferon/ribavirin.

Use of amantadine in relapsers to interferon and/or interferon/ribavirin {#ss17}
------------------------------------------------------------------------

Four trials (three observational studies and one open‐label randomized trial) have evaluated the role of amantadine in patients who responded but relapsed on prior therapy with interferon and/or interferon/ribavirin. Tabone *et al*. \[[43](#b43){ref-type="ref"}\] treated 40 interferon relapsers with amantadine monotherapy (amantadine 200 mg daily for 2 months); none of these patients achieved SVR. Carlsson *et al*. treated both nonresponders and relapsers to interferon/ribavirin combination with triple therapy (interferon 3 MU three times weekly, ribavirin 1000 mg daily, and amantadine 200 mg daily for 24 weeks), finding that 0% and 10% achieved SVR, respectively. This suggested that amantadine has no effect on nonresponders, but may result in SVR in a small number of relapsers to combination therapy \[[44](#b44){ref-type="ref"}\]. Weeginth *et al*. randomized 37 patients who responded but relapsed to previous interferon or interferon/ribavirin therapy to either of two triple therapy regimens. All patients received an initial 2 weeks of induction therapy with high‐dose interferon‐alpha 18 MU three times weekly, ribavirin, and amantadine, followed by 22 additional weeks of ribavirin and amantadine, with or without additional interferon‐alpha 3 MU three times weekly. None of the patients who received only 2 weeks of induction interferon achieved viral clearance; in contrast, a very high percentage (44%) of patients completing 24 weeks of triple therapy with induction and then standard interferon‐alpha achieved SVR (*P* \< 0.001) \[[45](#b45){ref-type="ref"}\]. This study demonstrated that re‐treatment with triple therapy may be highly effective in a small subset of relapsers to previous interferon or interferon/ribavirin therapy who have a non‐I genotype and demonstrated a virologic response within 6 weeks of initiating therapy.

Zilly *et al*. performed an observational study of 46 patients who were nonresponders to either interferon or interferon/ribavirin, relapser on interferon, or experienced a breakthrough on interferon or interferon/ribavirin. All patients were treated with triple therapy (interferon‐alpha 6 MU three times weekly, ribavirin 1000--1200 mg daily, amantadine 200 mg daily) for 6 months, and then interferon 6 MU three times weekly (monotherapy) for an additional 6 months. Although very few previous nonresponders achieved SVR with this regimen (6%), a significant number of patients who initially responded but relapsed on interferon, or experienced a breakthrough on interferon or interferon/ribavirin did achieve SVR (73, 71 and 66%, respectively) \[[46](#b46){ref-type="ref"}\]. These results suggested that re‐treatment with triple therapy may be highly effective in a select group of patients who have an initial response to interferon or interferon/ribavirin, but may have very little value in initial nonresponders.

### Summary {#ss18}

The role of amantadine in treatment of relapsers to interferon or interferon/ribavirin remains unclear. The current literature remains inadequate to properly assess its role in this population. However, these trials suggest that amantadine monotherapy and double therapy (interferon/amantadine or ribavirin/amantadine) do not appear to be effective in clearing virus. More importantly, this data additionally highlights that amantadine triple therapy (interferon/ribavirin/amantadine) may achieve significantly higher rates of sustained viral clearance in relapsers than in initial nonresponders. Although all of these studies were grossly underpowered to demonstrate a statistically significant difference, current data shows that amantadine may be a very promising adjunct in this target population, and should be studied in larger, randomized trials.

Use of amantadine in special populations {#ss19}
----------------------------------------

Few studies have examined the role of amantadine in special patient populations and these are summarized below.

### Elderly patients {#ss20}

The elderly remain an understudied population in the treatment of CHC infection \[[47](#b47){ref-type="ref"}\]. Most drug trials explicitly exclude patients aged over 60, and therefore little data is available to guide standards of care in these patients \[[48](#b48){ref-type="ref"}\]. This paucity of data is reflected in the original 1997 NIH Consensus Development Statement on Management of Hepatitis C, which did not support the routine use of interferon‐based therapy in patients aged over 60 years 'because of incomplete data' \[[49](#b49){ref-type="ref"}\]. Although no formal recommendation is made in the most recent Consensus Statement in 2002, it is clear that controversy remains over the safety and efficacy of interferon‐based therapy in this population, and the balance between risks and benefits. Newer regimens using antiviral agents with a favourable side effect profile are needed to provide alternative options for patients in whom interferon or ribavirin may be contraindicated. Amantadine is typically well‐tolerated, has few side effects (nausea, lightheadedness, decreased concentration, decreased appetite and anxiety), and rarely causes more serious reactions (agitation, hallucinations, seizures) \[[50](#b50){ref-type="ref"}\]. Torre *et al*. treated 23 consecutive treatment‐naïve elderly patients with CHC aged over 65 (mean age 70.1) with amantadine monotherapy \[[20](#b20){ref-type="ref"}\]. Although treatment was found to be safe with few side effects, amantadine failed to achieve either a sustained biochemical or virologic response. In summary, amantadine appears to be safe, well‐tolerated medication for the elderly, but is not effective for CHC.

### HCV‐HIV co‐infection {#ss21}

Treatment of HCV patients co‐infected with human immunodeficiency virus (HIV) continues to be an important challenge. As highly active antiretroviral therapy has resulted in markedly improved life spans in patients with HIV infection, liver disease has become an increasingly common cause of morbidity and mortality in this population. There are no therapies currently approved by the United States Food and Drug Administration for HIV‐HCV co‐infection, and the most recent NIH Consensus Development Conference Statement in 2002 recommended that treatment should be considered on a case‐by case basis, particularly in those with stable HIV infection and well‐compensated liver disease \[[51](#b51){ref-type="ref"}\]. Several small trials have suggested that combination interferon‐alpha/ribavirin is safe and well‐tolerated in these patients, and may achieve rates of sustained viral clearance similar to those of HCV mono‐infected patients \[[52](#b52){ref-type="ref"}, [53](#b53){ref-type="ref"}, [54](#b54){ref-type="ref"}, [55](#b55){ref-type="ref"}\]. Pegylated interferon in this population will likely be superior to standard combination interferon‐alpha and ribavirin. Sax *et al*. performed a pilot study in which nine patients with HIV co‐infection on antiretroviral therapy were treated with interferon‐alpha with or without amantadine. Neither treatment regimen resulted in SVR, suggesting that the addition of amantadine to interferon has little effect in this patient population \[[19](#b19){ref-type="ref"}\].

### Recurrent hepatitis C postliver transplantation {#ss22}

Hepatitis C infection recurs in nearly all patients following liver transplantation for HCV‐related cirrhosis, and may contribute to accelerated rates of fibrosis in some patients \[[56](#b56){ref-type="ref"}\]. Routine chemoprevention and treatment is not currently recommended in this setting in the absence of data \[[51](#b51){ref-type="ref"}\]. Although the data is limited, small studies have demonstrated that combination interferon‐alpha and ribavirin may be effective in some patients, but is poorly tolerated in most, requiring drug reduction or withdrawal \[[57](#b57){ref-type="ref"}, [58](#b58){ref-type="ref"}, [59](#b59){ref-type="ref"}, [60](#b60){ref-type="ref"}\]. Pilot data presented at the September 2003 American College of Gastroenterology conference suggests that pegylated interferon/ribavirin achieves high rates of sustained viral clearance in those patients who are able to complete 12 months of therapy, but treatment withdrawal occurs in nearly 50% of patients \[[62](#b62){ref-type="ref"}\]. Clearly, newer regimens with better tolerated agents are needed. Andreone *et al*. studied nine consecutive patients with recurrent post‐transplantation hepatitis C infection by administering triple therapy (interferon‐alpha 3 MU three times weekly, ribavirin 600 mg daily, and amantadine 100 mg daily) for 12 months. Unfortunately, the treatment was very poorly tolerated, with two requiring discontinuation within the first 3 months; only one patient was able to complete 12 months of therapy. During treatment, triple therapy did significantly decrease ALT levels below baseline, but only the patient who completed treatment achieved SVR (11%). Histological improvement on liver biopsy was seen in two patients \[[61](#b61){ref-type="ref"}\]. This suggests that triple therapy with amantadine in post‐transplant patients may result in viral clearance, but few are able to tolerate therapy for 12 months.

Impact of amantadine on the quality of life {#ss23}
-------------------------------------------

One study evaluated the impact of amantadine on health‐related quality of life when used in interferon nonresponders. This analysis showed substantial improvement of depression scores, and in the Profile of Mood States scale in the subscales fatigue (*P* \< 0.05) and vigour (*P* \< 0.05) among patients receiving interferon‐alpha and amantadine compared with those receiving interferon‐alpha alone \[[33](#b33){ref-type="ref"}\], most likely because amantadine reduced the side‐effects of IFN. Previous studies have demonstrated that interferon‐based regimens may significantly improve quality of life scores along all subscales of the SF‐36 survey instrument after treatment, particularly in those patients who achieved SVR. Although the mechanisms of action remain unclear, amantadine may improve quality of life by ameliorating symptoms associated with CHC infection and/or side‐effects of interferon therapy.

Discussion {#ss24}
==========

Our review of the published data suggested that amatadine may have a minor role in the treatment of CHC, although many issues remain unresolved. The optimal formulation and dosage of amantadine, for example, has been poorly studied. Although amantadine hydrochloride has been the primary drug form studied in research trials, several investigators have used amantadine sulphate in combination regimens. It is possible that the choice of formulation may affect treatment outcomes. In the meta‐analysis of interferon--amantadine combination therapy in treatment naïve patients, there was a significant difference in the response rate among patients who received amantadine hydrochloride instead of amantadine sulphate (*P* = 0.02) (64). The typical dose used in these studies ranged between 100 and 200 mg daily, although it is unknown if higher doses would result in higher efficacy. Major drawbacks of existing data include small sample sizes, widely divergent selections of patients and treatment protocols. Several studies did not stratify patients according to genotypes, a major predictor of response to interferon‐based therapy. This may explain some of the differences in results observed in different countries, as genotype distribution is largely regional in nature. In addition, several studies used nonstandard doses of interferon with or without induction, making comparison or pooling of data difficult. However, these studies demonstrate that amantadine is not effective as monotherapy, and poorly effective when used with interferon alone.

Amantadine may be useful as a safe, and well‐tolerated adjunct to combination interferon/ribavirin therapy in the treatment of some patients who have failed interferon or interferon/ribavirin for CHC infection ([Table 1](#t1){ref-type="table"}). The major advantage of amantadine is its favourable safety and tolerability profile and low cost. Although it is a weak antiviral agent with indirect effects on viral replication, multiple observational studies and randomized trials suggest that combination regimens with amantadine may significantly increase rates of sustained viral clearance in nonresponders, responder/relapsers, and breakthrough responders to interferon and interferon/ribavirin. In the absence of available therapies which target the HCV viral replication cycle, amantadine may represent a suitable option in the properly selected patient. Larger, randomized trials are needed to further define the role of amantadine in management of hepatitis C infection, particularly in combination with newer pegylated interferon‐based regimens, and in special understudied populations such as the elderly, and patients with HIV‐coinfection or recurrent HCV following liver transplantation.

###### 

Summary of clinical trials of amantadine combination therapy in nonresponders

                                                      Study description                                       No. of patients   Drug regimens used                                                                                     \% HCV‐1 genotype   Viral load (×10^6^ copies/mL)   Fibrosis/ cirrhosis                                      Type of nonresponder                                                                       Statistical tests used                                       Response rate at end of treatment                                                                                                                                         Percent sustained response at post‐treatment follow up
  --------------------------------------------------- ------------------------------------------------------- ----------------- ------------------------------------------------------------------------------------------------------ ------------------- ------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------
  Khalili *et al*. \[[35](#b35){ref-type="ref"}\]     Randomized, open label                                  29                IFN‐*α* + ribavirin *vs* IFN‐*α* + amantadine                                                          82.8%               2.85                            Fibrosis: 48.3%                                          IFN‐*α* monotherapy nonresponders                                                          Two‐tailed Student\'s *t* test, Fischer\'s exact test        36% in IFN‐*α* + ribavirin group; 0% in IFN‐*α* +  amantadine group (*P* = 0.017)                                                                                         15% in IFN‐*α* +  ribavirin group; 0% in IFN‐*α* +  amantadine group (*P* = NS)
  Younossi *et al*. \[[36](#b36){ref-type="ref"}\]    Randomized, double‐blinded, controlled multi‐centred    118               IFN‐*α* + ribavirin *vs* IFN‐*α* + amantadine                                                          77.1%               70.9% \>2.0                     Cirrhosis: 17.1%                                         IFN‐*α* monotherapy nonresponders                                                          Wilcoxon rank sum, chi‐square, or Fischer\'s exact test      19.8% in IFN‐*α* + ribavirin group; 14.7% in IFN‐*α* +  amantadine group (*P* = 0.60)                                                                                     3.9% in IFN‐*α* +  ribavirin group; 0% in IFN‐*α* +  amantadine group (*P* = 0.16)
  Teuber *et al*. \[[33](#b33){ref-type="ref"}\]      Randomized, placebo‐controlled, double blinded          55                IFN‐*α* + amantadine *vs* IFN‐*α* + placebo                                                            92.5%               7.6                             Fibrosis Mild: 29%  Mod: 40.5%  Severe: 23.6%            IFN‐*α* monotherapy nonresponders                                                          One‐tailed Fischer\'s exact test                             4% in IFN‐*α* + amantadine group; 14% in IFN‐*α* +  placebo group (*P* = not reported)                                                                                    0% in IFN‐*α* +  amantadine group; 7% in IFN‐*α* + placebo group (*P* = not reported)
  Brillanti *et al*. \[[38](#b38){ref-type="ref"}\]   Prospective, randomized, open‐label, controlled         60                IFN‐*α* + ribavirin *vs* IFN‐*α*, ribavirin, +  amantadine                                             56.7%               5.48                            Cirrhosis: 25%                                           IFN‐*α* monotherapy nonresponders                                                          Two‐tailed Wilcoxon signed‐rank and Fischer\'s exact tests   10% in dual therapy group; 67% in triple therapy group (*P* \< 0.0001)                                                                                                    5% in dual therapy group; 48% in triple therapy group (*P* \< 0.001)
  Adinolfi *et al*. \[[39](#b39){ref-type="ref"}\]    Prospective, open‐label, randomized trial               114               IFN‐*α* + ribavirin vs. induction IFN‐*α* + ribavirin vs. induction IFN‐*α*, ribavirin, + amantadine   71%                 3.0                             Cirrhosis: 27.2%                                         IFN‐*α* monotherapy nonresponders                                                          Fischer\'s exact and chi‐square tests                        25% in dual therapy group; 29% in induction dual therapy group; 67% in induction triple therapy group (*P* = 0.001)                                                       2% in dual therapy group; 4% in induction dual therapy group; 25% in induction triple therapy group (*P* = 0.002)
  Younossi *et al*. \[[42](#b42){ref-type="ref"}\]    Open‐label, pilot study                                 20                IFN‐*α*, ribavirin, +amantadine                                                                        85%                 1.8                             No reported                                              Failed to respond to IFN‐*α* monotherapy and IFN‐*α* + ribavirin dual therapy              Wilcoxon rank, Fischer\'s exact, and Kaplan--Meier           15% in triple therapy group                                                                                                                                               10% in triple therapy group
  Zilly * et al*. \[[46](#b46){ref-type="ref"}\]      Open‐label, pilot study                                 46                IFN‐*α*, ribavirin, +amantadine                                                                        84.8%                1.85                           HAI stage score: 1.76                                    IFN‐*α* monotherapy nonresponders *vs* IFN‐*α* + ribavirin dual therapy nonresponders      Chi‐square test                                              6.25% of previous dual nonresponders; 11.1% of previous monotherapy nonresponders                                                                                         6.25% of previous dual nonresponders; 0% of previous monotherapy nonresponders
  Berg * et al*. \[[32](#b32){ref-type="ref"}\]       Open‐label, pilot study                                 14                Induction IFN‐*α*, ribavirin, +amantadine                                                              92.9%               13.6                            Mild: 28.6%  Mod: 64.3%  Cirrhosis: 7.1%                 IFN‐*α* monotherapy nonresponders                                                          Not reported                                                 14% in triple therapy group                                                                                                                                               0% in triple therapy group
  Teuber * et al*. \[[63](#b63){ref-type="ref"}\]     Randomized, open‐label                                  225               Induction IFN‐*α* +  ribavirin *vs* Induction IFN‐*α*, ribavirin, +amantadine                          92.5%               67% had a high viral load       Mild: 52.6%  Mod: 32.1%  Severe: 7.9%  Cirrhosis: 7.4%   IFN‐*α* monotherapy non‐responders or IFN‐*α* + ribavirin or amantidine   non‐responders   Chi‐square test                                              37% in triple therapy group;   29% in dual therapy group   (*P* = 0.187)                                                                                                  25% in triple therapy group; 18% in dual therapy group (*P* = 0.201)
  Afdhal * et al*. \[[64](#b64){ref-type="ref"}\]     Prospective, randomized, controlled, open‐label study   118               PEG‐IFN‐*α* + ribavirin *vs* PEG‐IFN‐*α* + amantadine *vs* PEG‐IFN‐*α*, ribavirin, +amantadine         90%                 67% had a high viral load       No reported                                              IFN‐*α* + ribavirin dual therapy nonresponders                                             Not reported                                                 30% PEG‐IFN‐*α* +  ribavirin group; 18% PEG‐IFN‐*α* +  amantadine group; 38% PEG‐IFN‐*α*, ribavirin, + amantadine                                                         Not reported
  Lawitz *et al*. \[[65](#b65){ref-type="ref"}\]      Randomized, controlled, open‐label                      436               PEG‐IFN‐*α* + ribavirin *vs* PEG‐IFN‐*α*, ribavirin, +amantadine                                       84%                 Not reported                    Metrovir fibrosis stage: 44%                             IFN‐*α* monotherpay nonresponders *vs* IFN‐*α* +  ribavirin dual therapy nonresponder      Not reported                                                 27% in dual therapy‐dual nonresponder group; 46% in triple therapy‐dual nonresponder group; 43% in dual therapy‐mono nonresponder group; 25% in mono nonresponder group   Not reported
